Evaluation of Prioritized Assessment for Older Patients Living With Frailty Presenting to the Emergency Department

August 25, 2025 updated by: Daniel Wilhelms, University Hospital, Linkoeping

The older population is getting older and growing in size worldwide. This requires healthcare to adapt to meet the complex medical and nursing needs of the older patient group. As older patients have varying health conditions with different levels of functions, their premise to handle acute, unexpected illness differs as well. This complicates matters for healthcare, especially emergency departments (ED) where resource allocation and identifying patients that are at greatest risk of negative health outcomes must be prioritized in a limited time.

When patients present to the ED, initial triage information such as vital signs and reason for visit determines the triage acuity for the patient. In Linköping, and large parts of Sweden, the triage tool RETTS (Rapid Emergency Triage and Treatment System) is used, where the highest priority is red (priority 1), then orange (priority 2), yellow (priority 3), green (priority 4) and blue (priority 5). However, this can be misleading when assessing older patients due to altered physiology with natural ageing and older patients are known to be under-triaged with existing triage systems.

The variation in functional capacity in older patients does not necessarily correlate with comorbidities and age and has been condensed to the term 'frailty'. It has been proposed that the frailty level corresponds more to biological age rather than chronological age. Frailty increases the risk of adverse outcomes such as falls, the need of in-hospital care, institutionalization, and mortality in which the risk is increased even in low acuity illnesses.

Frailty can be assessed by various means and based on the theory of cumulative deficit, frailty assessment instruments have been developed where frailty level increases with the amount of help needed from others. Different instruments have been compared in the ED and the Clinical Frailty Scale (CFS) have been deemed fit due to it being practical in a busy environment. The scale consists of 9 points where 9 is the highest level of frailty and the scale is usually dichotomized into "robust" and "living with frailty" where 5 points or above constitutes frailty. The prognostic value of CFS has previously been studied in the ED of University hospital of Linköping in Sweden with results indicating that the instrument should be used as an additional risk assessment in the ED.

Older patients often present with vague and complex symptoms to th ED, which could lead to prolonged ED stay due to the need of extensive medical workup or therapy. Long ED stays have been shown to increase both morbidity and mortality in older patients as well as risk of delirium and complications relating to care, especially in individuals living with frailty. In order to decrease the adverse events, aim to shorten ED length of stay (ED LOS) should therefore be a reasonable goal in clinical improvement work. Early identification of frailty in the ED may lead to rapid assessments and streaming of care for older patients which have shown to statistically significantly decrease ED LOS, which is why an early assessment by a physician potentially could decrease overall ED LOS. However, it is unknown how early assessed frailty could affect the ED visit itself.

In the beginning of 2025, the Emergency department of University hospital of Linköping launched a local guideline which recommended that patients aged 65 years or older visiting the ED should be assessed with CFS as early as possible, preferably in connection to triage. If the patients were assessed as living with frailty, the frailty score should be stated in the electronical overview of ED patients. The patient's needs of care should be induvidualized according to frailty level and the responsible clinical team should aim to decrease the ED length of stay for older patients living with frailty.

This study focuses on the outcomes of this newly implemented routine and aims to answer if recommended prioritization of older ED patients living with frailty leads to decreased ED LOS. Furthermore the study investigates if the clinical guidelines have an impact on time to the first assessment by a physician, admission rate, in-hospital length of stay, and mortality at 90 days

Study Overview

Study Type

Observational

Enrollment (Actual)

1217

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Östergötland County
      • Linköping, Östergötland County, Sweden, 581 85
        • Department of Emergency Medicine, University hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients visiting the ED in Linköping in the age of 65 years or older who have been assessed by CFS

Description

Inclusion Criteria:

  • 65 years of age or older
  • Assessed by CFS with the score being documented in the electronic journal

Exclusion Criteria:

  • Under the age of 65 years of age
  • Not assessed by CFS
  • Refusal of participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group
Patients aged 65 years or older visisting the ED who have been assessed for frailty. The control group were included before implementation of the local guidelines.
Intervention group
Patients aged 65 years or older visisting the ED who have been assessed for frailty. The intervention group were included after the implementation of the local guidelines.
In the beginning of 2025, the Emergency department of University hospital of Linköping launched a clinical guideline which stated that patients aged 65 years or older should be assessed with CFS as early as possible, preferably in connection to triage. If the patients were assessed as living with frailty, the frailty score should be stated in the electronical overview of ED patients. The patient's needs of care should be met according to frailty level and the responsible clinical team should aim to decrease the ED length of stay for older patients living with frailty.
Other Names:
  • Local guidelines regarding frailty in the Emergency Department

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ED length of stay
Time Frame: From enrollment until end of inclusion, approximately 4-8 weeks for each group
Length of stay in the ED measured in hours and minutes (data will be collected from the electronic health record)
From enrollment until end of inclusion, approximately 4-8 weeks for each group

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to the first assessment by a physician
Time Frame: From enrollment until end of inclusion, approximately 4 weeks for each group
Time to the first assessment by a physician (measured in minutes)
From enrollment until end of inclusion, approximately 4 weeks for each group
Admission rate
Time Frame: From enrollment until end of inclusion, approximately 4-8 weeks for each group
Proportion of patients in each group that were admitted, measured in amount of patients and percentage.
From enrollment until end of inclusion, approximately 4-8 weeks for each group
In-hospital length of stay
Time Frame: From enrollment until end of inclusion, approximately 4-8 weeks for each group
Length of in-hospital stay, measured in days.
From enrollment until end of inclusion, approximately 4-8 weeks for each group
Mortality up to 90 days
Time Frame: From enrollment until end of inclusion, approximately 4-8 weeks for each group
Proportion of patients who deceased up to 90 days post ED-visit, including mortality at ED and in-hospital mortality. Measured in amount of patients and percentage.
From enrollment until end of inclusion, approximately 4-8 weeks for each group
Difference in ED length of stay between patients in different triage categories
Time Frame: From enrollment until end of inclusion, approximately 4-8 weeks for each group
Difference in ED length of stay between patients in different triage categories, measured in hours and minutes. The triage categories are: Red (priority 1), orange (priority 2), yellow (priority 3), green (priority 4), and blue (priority 5).
From enrollment until end of inclusion, approximately 4-8 weeks for each group

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2025

Primary Completion (Actual)

July 31, 2025

Study Completion (Actual)

July 31, 2025

Study Registration Dates

First Submitted

March 3, 2025

First Submitted That Met QC Criteria

March 9, 2025

First Posted (Actual)

March 11, 2025

Study Record Updates

Last Update Posted (Estimated)

August 26, 2025

Last Update Submitted That Met QC Criteria

August 25, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on Prioritized assessment for older patients living with frailty

Subscribe